Metabolex Overview

Metabolex is a privately held company founded to discover and develop therapeutics for diabetes. The company's lead product, MBX-102, is a novel insulin sensitizer currently in Phase I clinical trials. Metabolex's pipeline includes one product candidate in preclinical development, and three other programs optimizing lead drug candidates, one of which is partnered with Abbott Laboratories....More»

Metabolex is a privately held company founded to discover and develop therapeutics for diabetes. The company's lead product, MBX-102, is a novel insulin sensitizer currently in Phase I clinical trials. Metabolex's pipeline includes one product candidate in preclinical development, and three other programs optimizing lead drug candidates, one of which is partnered with Abbott Laboratories. Metabolex's two drug target discovery programs have produced one of the world's largest databases of diabetes-expressed genes. One of these programs, in insulin secretion, is partnered with Pfizer, Inc., and the other, in insulin resistance, is partnered with Yamanouchi Pharmaceuticals Co., Ltd.«Less